KEAP1 and lung carcinoma: SUMOylation of the endogenous levels of KEAP1 was demonstrated by immunoblotting peptides, which were enriched with an anti-KEAP1 antibody from human H1299 lung carcinoma cells untreated or treated with 2-D08, with an anti-SUMO1 antibody (Fig. 1H).